Tumor-associated macrophages (TAMs) are essential components of the cancer microenvironment and play critical roles in the regulation of tumor progression. Optimal therapeutic intervention requires in-depth understanding of the sources that sustain macrophages in malignant tissues. In this study, we investigated the ontogeny of TAMs in murine pancreatic ductal adenocarcinoma (PDAC) models. We identified both inflammatory monocytes and tissueresident macrophages as sources of TAMs. Unexpectedly, significant portions of pancreas-resident macrophages originated from embryonic development and expanded through in situ proliferation during tumor progression. Whereas monocyte-derived TAMs played more potent roles in antigen presentation, embryonically derived TAMs exhibited a profibrotic transcriptional profile, indicative of their role in producing and remodeling molecules in the extracellular matrix. Collectively, these findings uncover the heterogeneity of TAM origin and functions and could provide therapeutic insight for PDAC treatment.
In Brief Zhu et al. identify tissue-resident macrophages of embryonic origin as a source of tumor-associated macrophages in pancreatic ductal adenocarcinoma. These cells expand through in situ proliferation during tumor progression and demonstrate a unique pro-fibrotic transcriptional profile distinct from that of their monocyte-derived counterparts.
SUMMARY
Tumor-associated macrophages (TAMs) are essential components of the cancer microenvironment and play critical roles in the regulation of tumor progression. Optimal therapeutic intervention requires in-depth understanding of the sources that sustain macrophages in malignant tissues. In this study, we investigated the ontogeny of TAMs in murine pancreatic ductal adenocarcinoma (PDAC) models. We identified both inflammatory monocytes and tissueresident macrophages as sources of TAMs. Unexpectedly, significant portions of pancreas-resident macrophages originated from embryonic development and expanded through in situ proliferation during tumor progression. Whereas monocyte-derived TAMs played more potent roles in antigen presentation, embryonically derived TAMs exhibited a profibrotic transcriptional profile, indicative of their role in producing and remodeling molecules in the extracellular matrix. Collectively, these findings uncover the heterogeneity of TAM origin and functions and could provide therapeutic insight for PDAC treatment.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense fibrotic stroma and extensive infiltration by myeloid cells. Of these myeloid cells, tumor-associated macrophages (TAMs) are one of the most abundant. TAMs are known to promote tumor growth by releasing growth factors, inhibiting immune surveillance, and enhancing angiogenesis, among other mechanisms. Therefore, high numbers of TAMs correlate with poor patient outcome (Ino et al., 2013; Kurahara et al., 2011) , making macrophages a highly desirable therapeutic target.
Optimal therapeutic strategies targeting TAMs require an indepth understanding of their ontogeny and mechanisms governing their homeostasis. The traditional view holds that tissue macrophages are derived from circulating monocytes. However, emerging evidence suggests that various types of tissue-resident macrophages are established during embryonic development, persist into adulthood, and self-maintain independently of the adult hematopoietic system (Ginhoux and Guilliams, 2016; Gomez Perdiguero et al., 2015; Schulz et al., 2012) . Under homeostatic conditions, macrophages derived from different developmental origins co-exist in many organs. Two notable exceptions are brain microglia, which are generated during yolk sac hematopoiesis (Ginhoux et al., 2010; Hoeffel et al., 2015) , and intestinal macrophages, which rely on continuous replenishment by adult blood monocytes (Bain et al., 2014) . Macrophages in many other organs, including the pancreas, have mixed origins (Calderon et al., 2015) . A limited number of studies suggest that macrophages derived from different developmental origins have both overlapping and distinct functions within the same tissue (Epelman et al., 2014; Gibbings et al., 2015) . However, our understanding of the persistence and function of macrophages derived from different origins under pathologic conditions, such as cancer, is still limited.
In this study, we document a previously unappreciated heterogeneity in the ontogeny of TAMs in PDAC. We identify both Ly6C hi monocytes and tissue-resident macrophages of embryonic origin as sources of TAMs. Notably, TAMs derived from different origins demonstrate distinct phenotypes and divergent functionality. Whereas monocyte-derived TAMs are more potent at sampling tumor antigens, embryonically derived TAMs have higher expression of pro-fibrotic factors. These data reveal a potential novel function of embryonically derived macrophages and suggest a previously unknown interaction between TAMs and the fibrotic stroma of PDAC. 
RESULTS

Pancreatic Ductal Adenocarcinoma Tissues Are Infiltrated by Macrophages
High amounts of fibrosis and extensive immune cell infiltration characterize the tumor microenvironment of human PDAC. Among the infiltrating cells, macrophages are frequently a dominant component. This can be readily observed via comparison of the expression of pan-macrophage markers CD68, CD163, and CD206 in paired human pancreatic tissue samples containing both PDAC lesions and adjacent normal tissue (Figures 1A and 1B) . This increase in macrophage number parallels the amount of tissue fibrosis. Although tumor infiltration by macrophages is well characterized, the sources of these cells are not well understood.
To explore the ontogeny of TAMs in PDAC, we analyzed the p48-CRE + Lox-stop-Lox Kras G12D p53 flox/+ (KPC) genetically engineered mouse model, which undergoes stepwise progression through stages of pancreatic intraepithelial neoplasia (PanIN) and ultimately develops PDAC (Hingorani et al., 2005) . The KPC model faithfully recapitulates many pathological features of human PDAC, including progressive development of fibrosis and extensive accumulation of macrophages ( Figure 1C S1 ). We confirmed macrophage identity in our gating strategy on the basis of the expression of CD68, MerTK, CD64, colonystimulating factor 1 receptor (CSF1R), and CX3C chemokine receptor 1 (CX3CR1), but not Siglec-F or Zbtb46, in Zbtb46 GFP/+ reporter mice . Flow cytometry of tissues from the KPC model demonstrated a 24-fold increase in the total number and a 5-fold increase in the density of macrophages in end-point PDAC than in normal pancreas ( Figure 1F ). Similarly, macrophage numbers expanded in orthotopic PDAC tissues as the tumors progressed ( Figure 1G ). The marked increase in macrophages in PDAC mouse models mimics that seen in human pancreatic cancer.
Subsets of Macrophages in PDAC Are Maintained Independently of Blood Monocytes
To test the contribution of blood monocytes to macrophages in tumors, we first performed parabiosis by surgically joining the CD45.2 + KPC mice with CD45.1 + congenic wild-type mice. Parabiotic pairs were set up at 3.5 months of age, when KPC mice had developed extensive PanIN lesions but lacked frank PDAC lesions. We then analyzed chimerism up to 6 weeks, when KPC mice had progressed to late-stage PDAC. We observed 28% chimerism of Ly6C hi monocytes in the blood of KPC mice within the first 2 weeks, which did not increase further after 6 weeks of parabiosis (Figures 2A and 2B ). However, in steady-state pancreas, tissue macrophages achieved only 2.5% chimerism after 6 weeks ( Figure 2B ), suggesting that the majority of macrophages were maintained independently of circulating monocytes during this time period. Interestingly, the chimerism of macrophages in KPC tumors was only 8.8%, whereas Ly6C hi monocytes in the same tissue showed 27%.
We observed similar chimerism at both 2 and 6 weeks in spite of significant increases in macrophage numbers during this time period (Figures 1F and 2B) . These data suggest that although monocytes contribute to the expansion of macrophages during PDAC progression, they might not be the sole source of macrophages. Macrophages in tumors exist in subsets with distinct molecular phenotypes. One approach to identifying TAM subsets is based on differential expression of major histocompatibility class II (MHCII) (Movahedi et al., 2010) . To determine whether monocytes replenish these subsets differentially, we analyzed the tumor tissue after parabiosis. We found that the MHCII hi subset constituted up to 80% of the donor-derived TAMs, suggesting that monocytes preferentially, but not exclusively, replenish MHCII hi TAMs ( Figure 2C ).
To complement these parabiosis studies, we established bone marrow chimeras by lethally irradiating wild-type CD45.2 + mice and adoptively transferring bone marrow cells from CD45.1 + wild-type mice. 6 weeks after transfer, >99% of the immune cells in the blood and bone marrow of host mice were donor derived ( Figure 2D ). Despite potential elimination of radio-sensitive tissue-resident macrophages, 30% of macrophages in the pancreas were host derived ( Figure 2D ). In parallel, we lethally irradiated 3.5-month-old KPC mice at the PanIN stage, adoptively transferred bone marrow cells from CD45.1 + wild-type mice, and analyzed chimerism 6 weeks later in fully established PDAC. Similarly, a significant portion (>15%) of TAMs in KPC tumors were host derived ( Figure 2G ). These data confirm the presence of pancreas-resident TAMs that are not rapidly replaced by blood. Consistent with the parabiosis studies, hostderived (CD45.2 + ) macrophages were preferentially, but not exclusively, MHCII lo ( Figures 2E, 2F , and 2H).
To further assess the short-term contribution of blood monocytes to TAMs, we used fluorescently labeled latex beads to selectively trace Ly6C hi blood monocytes in tumor-bearing mice and analyzed fluorescent signals in the TAM compartments 12, 24, 48, and 72 hr after labeling ( Figure S2C ) (Tacke et al., 2006) . Whereas fluorescent beads labeled 25% of blood monocytes within 24 hr, which is the peak time for fluorescence detection in blood (Tacke et al., 2006) , bead signal was observed in a negligible amount of macrophages (<0.5%) in normal pancreas ( Figure 2I ) and 12% of TAMs in orthotopic PDAC tumors ( Figure 2I ). These data suggest that tumors upregulate the recruitment of circulating Ly6C hi monocytes to replenish a portion of TAMs. Consistent with bone-marrow-transplant and parabiosis results, bead-labeled monocytes almost exclusively replenished the MHCII hi TAM subset (Figures 2J and 2K) , and this replenishment persisted through 72 hr after bead injection ( Figure S2D ).
Impairment of Circulating Monocytes Alone Does Not Affect PDAC Progression
To determine the long-term contribution of blood monocytes to macrophages in the pancreas, we evaluated pancreas and PDAC macrophages in CCR2-and Nur77-deficient mice, which have impairments in circulating Ly6C hi and Ly6C lo monocytes, respectively (Boring et al., 1997; Hanna et al., 2011) . Despite a >95% reduction in the number of circulating Ly6C hi monocytes (Figures 3A and S3A) , the frequency of macrophages in steady-state pancreas remained unchanged in Ccr2 À/À mice ( Figure S3B ), and PDAC-infiltrating macrophages were only 50% lower than in Ccr2 +/À mice ( Figures 3B and S3C ). Consistent with the monocyte labeling experiments, CCR2 deficiency decreased MHCII hi TAM frequency, whereas MHCII lo TAMs
were not affected ( Figure 3C) . Surprisingly, despite the reduced macrophage numbers, CCR2 deficiency did not affect tumor growth in two independent PDAC models ( Figures 3D and  S3D ). Additionally, we observed no changes in tumor burden in KPPC GEMMs treated with CCR2 inhibitors continuously for 45 days ( Figure 3K ). To address the possibility that Ly6C lo monocytes might contribute to macrophages in PDAC tissues, we analyzed nur77 À/À mice. Similar to a previous report (Hanna et al., 2011) , we observed 75% fewer circulating Ly6C lo monocytes in nur77 À/À mice than in nur77 +/À littermates (Figures 3E and S3A). However, neither macrophage numbers nor their MHCIIsubset distribution was changed in normal pancreas or PDAC tissues ( Figures 3F and 3G ). Additionally, Nur77 deficiency did not affect PDAC tumor growth in three PDAC models (Figures 3H and S4E) . Together, these data suggest that circulating Ly6C hi monocytes are important for sustaining MHCII hi macrophages but dispensable for tumor progression.
Tissue-Resident Macrophages Promote PDAC Progression
To determine whether tissue-resident macrophages regulate tumor growth, we treated tumor-naive mice with CSF1-neutralizing antibodies in combination with clodronate-liposomes (CLDs), followed by a 10-day chase period to allow mice to recover circulating monocyte numbers. After the 10-day recovery, we found that circulating monocyte numbers in aCSF1-CLD-treated animals were restored to control levels ( Figure 3I ). By contrast, pancreas-resident macrophages were depleted as early as 12 hr after injection and remained depleted by 85%-95% after 10 days of recovery ( Figures 3I and S3F ). This suggests that this regimen allows us to test the loss of tissue-resident macrophages while leaving circulating inflammatory monocytes intact. To study how loss of resident macrophages affects tumor progression, we established orthotopic PDAC tumors 10 days after aCSF1-clodronate or IgG-PBS treatment. Loss of resident macrophages at implantation resulted in a 50% reduction in TAMs in established tumors (Figures 3I and S3F) , suggesting that loss of resident macrophages was not fully compensated for by monocyte recruitment. In contrast to observations in CCR2-null mice, depletion of pancreas-resident macrophages led to a significant reduction in tumor burden, as measured by both bioluminescence imaging (BLI) and tumor weight in two distinct PDAC models (Figures 3J and S3G) . To exclude the possibility that the impaired tumor progression was due to deficient tumor ''seeding'' upon implantation, we treated two genetic PDAC models (KPC and KPPC mice) with aCSF1-CLD at the premalignant PanIN stage and analyzed tumor burden after mice had progressed to PDAC. In both KPC and KPPC models, depletion of resident macrophages resulted in significant reduction in tumor burden (Figures 3K). By contrast, continuous treatment of KPPC-mice with CCR2 inhibitors during the same time period did not affect tumor burden (Figures 3K) . Additionally, analysis of tumor pathology in KPPC mice showed that depletion of resident macrophages dramatically reduced the development of high-grade invasive tumors and PDAC cell proliferation (Figures 3L and 3M) . Together, these data suggest that pancreas-resident macrophages are more potent drivers of PDAC progression than their monocyte-derived counterparts.
Embryonically Derived Macrophages Are Expand during Tumor Progression
To determine whether tissue-resident macrophages are derived from the adult hematopoietic system, we performed lineage (Schulz et al., 2012) . To validate this model, we analyzed circulating leukocytes and found that >95.5% of cells in the blood, including both Ly6C hi and Ly6C lo monocytes, were YFP + ( Figure 4A ). We analyzed colon macrophages and brain microglia as controls. Consistent with previous reports (Bain et al., 2014; Ginhoux et al., 2010) , in adult mice, 93% of the macrophages in the colon were YFP + and 98.8% of brain microglia were YFP À ( Figure 4B ). Figures 4C and 4D ). More strikingly, the number of YFP À macrophages was >29-fold higher in tumors than in normal pancreas ( Figure 4E ). Immunofluorescence analysis also identified clear subsets of both YFP + and YFP À macrophages in normal pancreas and PDAC tissues ( Figure 4F ). These data suggest that a significant portion of TAMs in PDAC tissues are derived independently of HSCs and expand rapidly during tumor progression. The presence of large numbers of YFP À macrophages suggests that many TAMs could be derived during embryonic hematopoiesis. Alternatively, these cells could have originated from adult HSCs without going through extensive Flt3 + stages. To distinguish between these two possibilities, we treated Flt3-Cre YFP mice with one dose of a CSF1R antibody (aCSF1R) on embryonic day 13.5 (E13.5) to deplete macrophages derived from embryonic sources (Hoeffel et al., 2015) . We found that treatment with aCSF1R on E13.5 resulted in an 80% reduction in the density of YFP À macrophages in the pancreas of F1 progeny at 6 weeks of age ( Figure 4G ). To further confirm the contribution of embryonically derived macrophages to TAMs in PDAC, we orthotopically implanted KPC cells in adult mice after aCSF1R treatment on E13.5. Embryonic aCSF1R treatment resulted in a 40%-60% reduction in the number of macrophages in established tumors ( Figure 4H ). Additionally, the loss of embryonically derived macrophages led to delayed tumor progression in two distinct syngeneic PDAC models ( Figure 4I ). Together, these data suggest that embryonically derived macrophages facilitate PDAC progression.
To further assess the specific contribution of embryonic hematopoietic progenitors to PDAC TAMs, we administered one dose of tamoxifen in Csf1r-mer-iCre-mer/LSL-tdTomato mice at E8.5, E9.5, E10.5, E11.5, or E13.5 to span yolk sac and fetal liver stages. Using this model, we observed that HSC-derived circulating monocytes were labeled at all time points later than E9.5 ( Figures S5A and S5B ). Using E8.5 and E9.5 tamoxifen pulsing, we observed labeling in 4% and 10% of macrophages, respectively, in normal pancreas as mice reached 6 weeks of age (Figures 5A and 5B) . To confirm this, we used Cx3cr1-CreERT2/LSL-eYFP reporter mice and found after tamoxifen administration on E13.5 at the fetal liver stage, the majority of Ly6C hi monocytes were not labeled (Yona et al., 2013) , but a significant portion of pancreas tissue macrophages were labeled ( Figure S5C ). To assess whether the embryonically labeled macrophages would expand during tumor progression, we established orthotopic Kras-INK (KI)-derived PDAC tumors in Csf1r-mer-iCre-mer LSL-tdTomato mice. Consistent with results in Flt3-Cre YFP mice, tdTomato + macrophages labeled with a tamoxifen pulse at E8.5 or E9.5 expanded in number by 6.8-or 13.5-fold, respectively, during PDAC tumor progression (Figures 5C). These data suggest that yolk-sac-derived macrophages undergo significant numerical expansion during tumor progression. In both CSF1R-and CX3CR1-driven lineage-tracing models, we observed higher labeling in the MHCII lo macrophage subset (Figures S5D and S5E) . Similarly in the Flt3-Cre reporter mice, significantly larger portions of YFP À macrophages constituted the MHCII lo subset in both normal pancreas and PDAC tissues ( Figures S4C and S4D ), suggesting that embryonically derived TAMs are preferentially but not exclusively enriched in the MHCII lo subset. Interestingly, we found that in both HSCderived and embryonically derived TAMs, the MHCII lo subset experienced higher levels of hypoxia, but the TAM hypoxia level was independent of origin ( Figures S4E and S4F ). These data suggest that macrophage origin might drive intrinsic macrophage phenotype differences that can be further molded by the tumor microenvironment.
Embryonically Derived Macrophages Expand through In Situ Proliferation
To determine whether tissue-resident macrophages expand through local proliferation, we analyzed Ki67 expression and short-term 5-bromo-2 0 -deoxyuridine (BrdU) incorporation. Analyses of normal pancreas demonstrated that <1% of macrophages incorporated BrdU after a 3 hr pulse and that <3% were Ki67 + ( Figures 6A-6D ). These data suggest that pancreasresident macrophages in the steady state are mostly quiescent. By contrast, >15% of TAMs in either autochthonous KPC tissues or orthotopic KPC-1 tumors were Ki67 + , and 3.5%-4% were labeled with BrdU within 3 hr ( Figures 6A-6D ). Of note, the 3 hr pulse resulted in no detectable BrdU signal in circulating monocytes ( Figure S6A ), suggesting that BrdU signals in pancreatic macrophages reflect in situ proliferation. Immunofluorescence staining also identified a significant portion of Ki67 + F4/80 + cells in autochthonous KPC PDAC tissues ( Figure 6C ), but not in normal pancreas. Interestingly, the majority of these Ki67 + F4/ 80 + cells localized to fibrotic tumor areas ( Figures 6C and S6C ).
Consistent with this, macrophages cultured on high-density collagen I gels had higher proliferation rates ( Figure S6D ), suggesting that there could be cross talk between tumor fibrosis and macrophage proliferation. Microarray analysis of TAMs from autochthonous KPC tumors demonstrated distinct changes in cell-cycle regulatory genes in comparison with macrophages from normal pancreas ( Figure 6E ). To assess whether embryonically derived TAMs proliferate at higher rates than HSC-derived TAMs, we stained for Ki67 in tumor-bearing Flt3-Cre YFP mice. Embryonically derived TAMs had a significantly higher frequency of Ki67 positivity than their HSC-derived counterparts ( Figure 6F ). This increased level of Ki67 in embryonic TAMs was independent of their MHCII status ( Figure S6B ). In addition, transcriptional profiling by qPCR also identified significantly reduced level of genes that negatively regulate cell-cycle progression, such as Mafb and c-Maf, but higher levels of cell-cycle-promoting genes, such as Jun and Ets2, in the YFP À TAM subset ( Figure 6G ).
These data suggest that embryonically derived macrophages in PDAC tissues upregulate proliferative programs, perhaps in response to fibrosis, to keep pace with tumor progression.
We next tested which signals sustain the survival of these TAM subsets in PDAC tissues. We treated orthotopic PDAC-bearing Flt3-Cre YFP mice with neutralizing antibodies against CSF1 and CSF2, both of which have been implicated in macrophage survival in mouse models of cancer (Hoeffel et al., 2015; Zhu et al., 2014) . Although CSF2 signal blockade did not change the number of TAMs, inhibition of CSF1 signaling led to a 48% reduction in YFP + and a 75% reduction in YFP À macrophages ( Figure 6H ). These data suggest that CSF1 is important for the survival of both TAM subsets but that embryonically derived macrophages are more sensitive. Figure 7A ). Similar differences were also seen between the two macrophage subsets in normal pancreas (Figure S7B ), which suggests possibly inherent differences in antigen presentation. By contrast, co-stimulatory molecules (CD80 and CD86), T-cell-activating molecules (CD40), and immune checkpoint molecules (PDL1, PDL2, and PD1) were expressed at comparable levels ( Figure 7A ). Embryonically derived TAMs also expressed significantly higher levels of CX3CR1 and lower levels of CD11a and CD49d ( Figures 7A and S7C) . Interestingly, despite the lack of CXCR4 expression in either macrophage subset in the normal pancreas, CXCR4 was significantly upregulated in YFP À TAMs ( Figures 7A and S7B ). Together, these data suggest that TAMs derived from different origins are phenotypically distinct.
To gain further insight into potential functional differences between embryonically derived and HSC-derived macrophages, we performed transcriptional profiling on macrophages sorted from Flt3-Cre YFP mice ( Figures 7B and S7D) . Only a modest number of genes were expressed differentially between the YFP + and YFP À macrophages in steady-state pancreas. However, 660 genes were differentially expressed (>1.5-fold, p < 0.05) between the two subsets in orthotopic KPC tumors. Using gene-set enrichment analysis, we found that the genes enriched (G) Flt3-Cre YFP reporter mice were treated with aCSF1R on E13.5. Pancreas was isolated at 6 weeks of age. Density of YFP À macrophages was quantified (n = 3-5/group). (H) C57BL/6 mice were treated with aCSF1R or vehicle on E13.5. Orthotopic PDAC was established at 6 weeks of age. TAMs were quantified after 12 days (n = 5-6/group).
(I) Tumor burden from (H) was analyzed (n = 6-9/group). Data are shown as mean ± SEM, and asterisks denote p < 0.05 by t test. Panels (A)-(C) are pooled data from 3 experiments, and (G)-(I) represent 2 independent experiments.
in embryonically derived macrophages showed a strong trend toward poor survival when mapped to human PDAC datasets ( Figure S7E) . Analysis of gene ontology demonstrated that embryonically derived macrophages had a higher expression of molecules involved in extracellular matrix (ECM) deposition and remodeling ( Figure 7C ). Indeed, molecules on top of the list of genes that were expressed at higher levels in embryonically derived TAMs were mostly involved in ECM organization (Table S1 ). This included genes encoding ECM molecules (collagen isoforms, nidogen, tenascin C, and elastin), ECM-producing enzymes (hyaluronan synthases 2 and 3), and ECM-remodeling molecules (lysyl oxidase), which we validated by qPCR ( Figures 7D and S7F ). Correlating with their differential expression profiles, embryonically derived TAMs could produce significantly more collagen I and IV in ex vivo assays ( Figure 7F ). To correlate these ex vivo results to in vivo impact, we analyzed (legend continued on next page) collagen density in PDAC tissue from mice treated on E13.5 with aCSF1R or control IgGs and compared these results with those of CCR2-deficient mice. We found that embryonic macrophage depletion reduced collagen deposition. By contrast, CCR2-deficient mice had slightly elevated collagen levels ( Figure S7G ). These data suggest that macrophages of different origins have differential impacts on fibrosis.
To rule out the possibility that the identified YFP À cells contained fibroblasts, we compared cancer-associated fibroblasts (CAFs) with YFP À TAMs. We found that CAFs expressed platelet-derived growth factor receptor a (PDGFRa), but not CD45, F4/80, or CD11b ( Figure S7H) . Similarly, the mRNA expression levels of macrophage and myeloid identity genes (Emr1, Itgam, Csf1r, Csf2r, and Cx3cr1) were comparable in both YFP + and YFP À TAMs but were 10-to 1,000-fold higher in TAMs than in CAFs ( Figure S7I ). These data confirm that the YFP À cells
were not fibroblasts but were macrophages with a pro-fibrotic phenotype. To evaluate how the pro-fibrotic gene signature in embryonically derived TAMs might differ from that in CAFs, we compared selected genes by qPCR. As expected, CAFs were the dominant producers of several isoforms of collagens, Elastin, and Sparc, whereas YFP À TAMs expressed more Col4a4, Col10a1, Col17a1, Col18a1, and Has3 ( Figure S7J ). Together, these data suggest that embryonically derived TAMs might be involved in ''fine-tuning'' fibrotic responses in PDAC tumors. In contrast to pro-fibrotic genes, mRNA involved in class I and class II antigen presentation (Erap1, Psme1, and Ciita) was present at higher levels in HSC-derived TAMs ( Figure 7E ). To test the phagocytosis capacity in TAM subsets in vivo, we orthotopically implanted mCherry + KPC-1 cells and determined mCherry positivity in TAMs. Although both TAM subsets demonstrated a potent capacity to uptake tumor antigen, the amount of antigen uptake was >2-fold higher in HSC-derived TAMs ( Figure 7G ). We next tested the ability of each TAM subset to present antigen (ovalbumin) to OT1 + CD8 + T cells and found that HSC-derived (YFP + ) TAMs were far more potent at antigen presentation (Figure 7H ). In addition, YFP + TAMs expressed significantly higher levels of Il12a, Il4, Ccl17, and Ifnb1 ( Figure 7E ). Together, these data suggest that TAMs derived from HSCs might play more potent roles in regulating adaptive immunity. This is consistent with previous reports showing that monocyte-derived TAMs regulate immunosuppression in PDAC models (Beatty et al., 2015; Sanford et al., 2013) .
Subsets of TAMs in Human PDAC Tissue Resemble Murine Embryonically Derived TAMs
To evaluate whether the characterization of embryonically derived TAMs in murine PDAC models is relevant for human cancer, we took advantage of the observation that CXCR4 was almost exclusively upregulated in embryonically derived TAMs ( Figure 7A ) and evaluated human PDAC tissues for CXCR4 + TAMs. We found that 10%-40% of TAMs expressed high levels of CXCR4 ( Figure 7I ) and that these CXCR4 + TAMs expressed lower levels of HLA-DR in 8 out of 9 patient tissues ( Figure 7J ). These results were consistent with our observation that embryonically derived TAMs express lower levels of MHCII. To determine whether this subset of human TAMs had a pro-fibrotic gene expression profile similar to that identified in mice, we isolated mRNA from CXCR4 + and CXCR4 À TAMs from human PDAC tissues. Consistent with murine data, we found that CXCR4 + TAMs expressed significantly higher levels of collagens and ECM-remodeling genes ( Figure 7K ). Collectively, these data suggest that CXCR4 + TAMs in human PDAC resemble murine embryonically derived TAMs and could have the ability to finetune PDAC fibrosis.
DISCUSSION
Ontogeny of tissue macrophages varies in different tissues under steady state. With the exception of the brain and intestines, many other organs contain a variety of co-existing macrophages of different origins within the tissue context. Consistent with a previous report (Calderon et al., 2015) , our study demonstrated that pancreas-associated macrophages are derived from both adult HSCs and embryonic sources. Regardless of developmental origin, significant portions of macrophages in the pancreas are resident in the tissue and not rapidly replenished by monocytes. The majority of pancreas-resident macrophages are quiescent under steady state, suggesting that these cells could self-maintain through longevity. It is also important to note that ontogeny of tissue-resident macrophages is not static. Embryonically derived macrophages in multiple organs have various degrees of replacement with monocytes with different kinetics (Bain et al., 2016; Ginhoux and Guilliams, 2016; Molawi et al., 2014) . Our study using aged mice demonstrated that embryonically derived macrophages could persist in the pancreas over the long term, but the extent to which these macrophages could persist in aged humans remains to be seen. Fates of tissue-resident macrophages vary under different pathological conditions. For example, liver-resident Kupffer cells undergo necroptosis during Listeria monocytogenes infection, which recruits monocytes to replenish macrophages (Blé riot et al., 2015) . On the other hand, tissue macrophages undergo in situ proliferation during helminth infections (Jenkins et al., 2011) . Very few studies have looked at the fate of tissue-resident macrophages during cancer progression. One report documented a loss of resident macrophages and a concomitant increase in monocyte-derived TAMs in a breast cancer model (Franklin et al., 2014) . On the other hand, microglia remain present in brain tumor models (Bowman et al., 2016;  (D) Quantitation of flow-cytometry data for Ki67 and BrdU positivity in macrophages in normal pancreas and orthotopic KPC-1 tumors (n = 4-5/group from two independent repeats). (E) Heatmap of cell-cycle genes assessed by array on RNA in macrophages isolated from normal pancreas and autochthonous KPC-1 tissues (n = 6/group). (F) Orthotopic KPC-1 tumors were established in Flt3-Cre YFP mice. Proliferation of TAM subsets was analyzed by flow cytometry for Ki67.
(G) TAM subsets were sorted from orthotopic KPC-1 tumors in Flt3-Cre YFP mice. qPCR analyses were performed to quantify transcripts of proliferation-regulating genes.
(H) Orthotopic KPC-1-bearing Flt3-Cre YFP mice were treated with three doses of aCSF1 or aCSF2 on days 7, 11, and 14. TAM subsets were quantified on day 15.
Data are shown as mean ± SEM, and asterisks denote p < 0.05 by t test. Hambardzumyan et al., 2016) . Here, we have demonstrated that in PDAC, tissue-resident macrophages not only persist but also undergo significant expansion during PDAC progression. TAMs in PDAC tissues adopt a transcriptional program to enhance proliferation, and embryonically derived macrophages further enhance their proliferative programs in comparison with HSC-derived counterparts. Factors that sustain and promote in situ proliferation in different TAM subsets, as well as the cellular sources of these factors, have yet to be identified. The extent to which these observations would hold true in other cancers also remains to be seen. Answers to these questions could provide insights into how we can therapeutically target TAM subset-specific pathways in order to restrain the progression of different types of tumors. A highly debated question, and one that remains largely unsolved, is whether macrophage origin dictates functionality. A limited number of transcriptional studies have suggested that macrophages of different ontogeny demonstrate mostly overlapping transcriptional profiles within the same tissue, at least in nondisease settings (Gibbings et al., 2015; Gundra et al., 2014; van de Laar et al., 2016) . Upon engraftment, circulating monocytes could also replenish the resident macrophage pool and adopt a transcriptional profile similar to that of their embryonically derived counterparts . These studies suggest that tissue environment, as opposed to ontogeny, is the main driver of macrophage functions. However, our data demonstrate that although gene expression profiles of embryonically and HSCderived macrophages are fairly similar in the normal pancreas, their transcriptional profiles and ex vivo functions are very distinct in PDAC tissues. As a harbinger of this dynamic, CXCR4 is largely not expressed in macrophages of either origin in the normal pancreas but is specifically upregulated in PDAC TAMs of embryonic origin. These data suggest that origin could poise macrophages to differentially respond to inflammatory insults with distinct bioactivities. Future experiments are needed to determine which lineage commitment factors poise macrophages for differing functional responses during tumor progression.
Our study suggests potentially unique fibrosis-modulating functions in embryonically derived TAMs. Fibrosis is a hallmark of PDAC, as well as pancreas injury responses such as pancreatitis.
Macrophages are well known for their ability to promote fibrosis in various physiological and pathological conditions (Wynn and Vannella, 2016) by activating fibroblasts to secrete and remodel the ECM. Here, our data suggest that subsets of macrophages might fine-tune fibrosis by directly depositing and/or remodeling the ECM. Corresponding with this idea, a recent report demonstrated that TAMs directly construct the ECM in colon cancer (Afik et al., 2016) . Interestingly, such activities were carried out by monocyte-derived TAMs in their model. Strikingly, macrophages of different origins had different impacts on tumor progression in our PDAC models. Loss of monocyte-derived macrophages had limited effects on tumor progression, whereas depletion of tissue-resident macrophages significantly reduced tumor progression. These observations form a nice comparison to several other tumor models, where depletion of monocyte-derived macrophages inhibits tumor growth and metastasis (Afik et al., 2016; Franklin et al., 2014; Qian et al., 2011) . Although we cannot rule out the importance of monocyte-derived TAMs in the regulation of tumor immunity, our data suggest that tissue-resident macrophages are important for progression.
In summary, our study demonstrates that PDAC contains macrophages with heterogeneous origins. In addition to monocytes, tissue-resident macrophages derived from embryonic progenitors are also a major source of TAMs. Embryonically derived macrophages expand in PDAC tissues through in situ proliferation and exhibit a pro-fibrotic transcriptional profile. We provide a new paradigm of macrophage heterogeneity under the tumor setting, which could facilitate future investigations that ultimately improve therapeutics to target the ''fibro-inflammatory'' microenvironment of PDAC.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
freshly obtained from 9 patients at pancreaticoduodenectomy, and processed immediately for flow cytometry analysis and/or fluorescence-activated cell sorting. Four out of the nine patients have received neoadjuvant therapies, including FOLFIRINOX or ABRAXANE/gemcitabine prior to being scheduled for resection. All patients were off therapy for 21 days prior to surgery. All tissues were collected under informed consent from patients. Washington University Ethics committee approved the study under IRB protocol #201108117.
METHOD DETAILS Parabiosis
Parabiotic pairs were generated according to established protocols (Peng et al., 2013 ) from age-(3.5-month-old) and weightmatched female CD45.2 + (KPC or wild-type C57BL/6) and CD45.1 + (C57BL/6) mice. Mice were injected with Buprenex subcutaneously after surgery. Sulfatrim was continuously added in drinking water for 10 days post-surgery to minimize infections at surgical wounds. Mice were separated and perfused with phosphate buffered saline (PBS) containing 0.2% heparin. Single cell suspensions from tissues were stained with antibodies for flow cytometry analyses 2 or 6 weeks after the establishment of parabiosis.
Bone Marrow Transplantation
Three and a half-month-old C57BL/6 mice or KPC mice were exposed to g-irradiation dosed at 1,100 rads. Animals were subsequently injected with 2.5 3 10 6 bone marrow cells from CD45.1 + C57BL/6 mice through n). Leukocyte chimerism was analyzed 6 weeks later.
Macrophage Depletion
To deplete tissue resident macrophages, 8-16-week old C57BL/6 mice were treated with 3 doses of CSF1 neutralizing antibody (clone 5A1, BioXCell) (1 mg, 0.5 mg, 0.5 mg on Days À18, À14, and À11, Figure 3 Similarly, KPC and KPPC mice were treated with 2 doses of aCSF1 (0.5 mg each, Day 1 and Day 5) and 2 doses of clodronateloaded liposome (100 uL each, Day 3 and Day 7) starting at 2.5-month and 1-month of age, respectively. Tumor burden was analyzed when mice reached 4.5 months for KPC mice or 2.0 months for KPPC mice.
To deplete embryonically derived macrophages, C57BL/6 or Flt3-Cre YFP mice were intraperitoneally injected with 3.0 mgs of CSF1R depleting antibody (AFS98 clone, BioXCell) on 13.5 dpc. Surviving mice were implanted with 50,000 CBR + KPC-1 at 6 weeks of age. Mice were sacrificed 12 days after tumor establishment for flow cytometry and tumor burden analyses.
Lineage Tracing of Embryonically Derived Macrophages
Timed breeding was set up by crossing Csf1r-Mer-iCre-Mer mice with Rosa26-LSL-tdTomato mice (both on the FVB background). Embryonic timeline was assessed based on vaginal plug observation: 12pm on the day of plug formation was estimated to be 0.5 day post coitum (dpc). Pregnant mice were treated with tamoxifen (Sigma-Aldrich) (75 mg/g) combined with progesterone (Sigma-Aldrich) (37.5 mg/g) at one of the following time points: 8.5, 9.5, 10.5, or 13.5 dpc. To test the contribution of embryonically derived CSF1R + cells to monocytes or macrophages at homeostatic conditions, tumor-free F1 mice were sacrificed for fate mapping analyses as they reached 6 weeks of age. To test the contribution of embryonically derived CSF1R + cells to TAMs in PDAC tumors, 50,000 syngeneic Kras-INK cells were orthotopically implanted into F1 mice as they reached 6 weeks. Kras-INK cells were derived from p48-Cre/LoxStop-Lox (LSL)-Kras G12D /Ink4a-Arf lox/lox mice on the FVB background as previously described. Mice were sacrificed approximately 12 days after tumor implantation for the analyses of tdTomato signal in different leukocyte populations.
To trace CX3CR1+ cells, Cx3cr1-CreERT2 mice were crossed with Rosa26-LSL-eFYP mice (both on the C57BL/6 background). Pregnant mice were treated with tamoxifen (75 mg/g) and progesterone (37.5 mg/g) on 13.5 dpc. F1 neonates were fostered by lactating female mice and then aged to 6 weeks for fate mapping analyses.
Labeling of Blood Ly6C hi Monocytes
To selectively label Ly6C hi monocytes, 250 uL of liposomes containing clodronate were injected intraveneously (i.v.), followed by i.v.
injection of 250 uL of FITC-conjugated plain microspheres 16-18 hr later (1.0 um, 2.5% solids [wt/vol]; Polysciences, diluted 1:4 in PBS). Tissues were processed for flow cytometry analyses at indicated time points after bead injection.
Mouse Tissue Isolation and Flow Cytometry
Mice were euthanized by intracardiac perfusion using 20 mL of PBS-heparin under isoflurane anesthesia. Tumor tissues and colon were manually minced and digested in 25 mL of Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher) containing 2 mg/mL of collagenase A (Roche) and 13 DNase I (Sigma) for 30 min at 37 C with constant stirring. Normal pancreas was digested in the same buffer for 15 min at 37 C. Digestion was quenched in 5 mL of fetal bovine serum (FBS) (Atlanta Biologicals) and filtered through 40 mm Nylon mesh, pelleted through centrifugation (2,000 rpm for 5 min at 4 C), and resuspended in staining buffer (PBS containing 1% BSA). Brain and spleen were minced and triturated through 40 mm filters.
Single cell suspensions were blocked with rat anti-mouse CD16/CD32 antibodies (eBioscience) (1/200) for 10 min, pelleted by centrifugation, and subsequently labeled with 100 mL of fluorophore-conjugated anti-mouse antibodies at recommended dilutions for 20 min on ice, and washed with staining buffer. For proliferation assays, mice were injected with 5-bromo-2 0 -deoxyuridine (BrdU, 1 mg) i.p. 3 hr prior to sacrifice. BD Bioscience Cytofix/cytoperm kit was used to stain for BrdU. eBioscience transcription factor staining buffer set was used to stain for Ki67. Data were acquired on LSR-II (BD Biosciences), and analyzed using FlowJo software (Tree Star). To quantify proliferating/cycling cells in Flt3-Cre YFP mice, tumors were digested as described above, stained with fluorophore-conjugated antibodies for 20 min, fixed in 4% formaldehyde for 10 min on ice, permeabilized in ice-cold 70% ethanol for 3 hr, stained with Ki67 antibody diluted in staining buffer for 20 min on ice, pelleted and resuspended in staining buffer, and immediately processed for data acquisition on LSR-II. To assess hypoxia, Flt3-Cre YFP mice were intraperitoneally injected with pimonidazole hydroxychloride (60 mg/kg) 1 hr prior to sacrifice (Hypoxyprobe). Single cell suspensions were stained with antibodies against pimonidazole adducts for 20 min at 4 C without fixation or permeabilization prior to data acquisition.
To quantitate blood monocytes, 200 uL of blood was obtained by intracardiac puncture prior to perfusion, incubated in red blood cell lysis buffer (BioLegend) for 15 min on ice, and stained with fluorophore-conjugated antibodies for 20 min on ice. Stained cells were counted using LSR-II. For blood analysis that does not require numeration, blood was drawn via tail vein bleeding, followed by RBC lysis, antibody staining, and data acquisition.
Fluorescence-Activated Cell Sorting (FACS)
Normal or tumor-bearing mice (Flt3-Cre YFP , KPC, or C57BL/6 control) were perfused with 20 mL of heparin-containing PBS. Tissues were digested in 25 mL of DMEM containing 2 mg/mL of collagenase A (Roche) and 1X DNase I (Sigma) for 30 min at 37 C with constant stirring. CD45 + cells were enriched from single cell suspensions through MACS magnetic selection using anti-mouse CD45 microbeads (Miltenyi). Elutes were blocked with rat anti-mouse CD16/CD32 antibodies (eBioscience) (1/200) for 10 min, pelleted by centrifugation, and labeled with fluorophore-conjugated anti-mouse antibodies at recommended dilutions for 20 min on ice. Cells were filtered through 40 mm Nylon mesh, and immediately sorted using Aria-II (BD Biosciences). For microarray analyses and gene expression analyses, cells were sorted directly into RNA lysis buffer (Omega Biotek); RNA was isolated using the EZNA kit (Omega Biotek) according to instructions by the manufacturer. For ex vivo assays, cells were sorted into DMEM containing 20% FBS before being pelleted and resuspended for subsequent treatments.
Ex Vivo Antigen Presentation and Collagen Deposition Assays
For ex-vivo analysis of TAM subsets, macrophages were sorted from Flt3-Cre YFP mice as described above. To evaluate their potential for antigen presentation, sorted cells were added to 96 well round bottom plates at 40,000 cells per well and allowed to adhere for 2 hr in the presence of 10 mg/mL CSF1 (Peprotech). Cells were then washed with media and incubated with SIINFEKL peptide (Thermo, 2.5 mg/mL). During this time CD8+ OT1s were isolated from the spleen of tumor free mice using CD8 + magnetic bead selection (Miltenyi) and these T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) according to instructions from the manufacturer (Invitrogen). Macrophages were then washed twice with media and 40,000 CD8+ OT1's were added. Co-culture was done in Roswell Park Memorial Institute medium (RPMI)-1640 (GIBCO) supplemented 5% FBS, 13 beta mercaptoethanol (BME) and 5 mg/mL CSF1. Cells were analyzed for proliferating T cells after 36 hr by flow cytometry analysis of CD8a, CD44, CD62L and CSFE-dilution. For ex vivo analysis of collagen production, TAMs were isolated and cultured with 10 mg/mL CSF1 on glass chamber slides (Falcon). 20,000 TAMs were used per well. After 24 hr cells were fixed in PFA and analyzed for Collagen I or IV by standard immunofluorescent staining, as described above. Importantly cells were not permeabilized with detergent. Collagen content was accessed by fluorescent intensity per 203 field divided by cell number (DAPI + nuclei).
Sirius Red Staining and Immunofluorescence Staining
Tissues were isolated from perfused mice, fixed in 10% formalin overnight, incubated in graded ethanol, embedded in paraffin, and cut into 6-mm-thick sections. To analyze tumor fibrosis, tissue sections were deparaffinized in xylene, rehydrated in graded ethanol, and processed for Picro-Sirius Red staining according to instructions by the manufacturer (Sigma Aldrich). To visualize macrophages in mouse KPC and human PDAC tissues, paraffin sections were steam heated for antigen retrieval in citrate-based buffer (Biogenex), treated with 1% hydrogen peroxide (Invitrogen) for 20 min to quench endogenous peroxidase, incubated with blocking buffer (PBS containing 5% goat serum and 2.5% BSA) for 1 hr at room temperature (RT), blocked for biotin/avidin according to instructions by the manufacturer (Vector Labs), and stained with primary antibodies at recommended dilutions at 4 C overnight. Opal 4-color IHC kit was then used according to instructions by the manufacturer (PerkinElmer). When two antibodies were used for co-staining, FITC and Cy5 were used to minimize emission spectral overlap. To visualize YFP-positive macrophages in Flt3-Cre YFP mice, orthotopic PDAC tissues were fixed in 4% formaldehyde at 4 C overnight, incubated in PBS containing 30% sucrose and 0.1% sodium azide overnight at 4 C, and embedded in OCT compound on dry ice. Frozen sections (6 mm thick) were air-dried, treated with blocking buffer at RT for 1 hr, and stained with CD68 (1/200) (Abcam) overnight, followed by 1 hr incubation with goat anti-rabbit-Alexa594 (1/400) (Molecular Probes) at RT. All sections were washed in PBS containing 0.05% Tween-20 between incubation steps, and mounted in DAPI-containing media (Vector Labs) for imaging on Nikon 80i microscope.
PDAC Patient Outcome Analysis
We used top 110 genes whose expression was >10-fold higher in the mouse Flt3-Cre YFPÀ TAM subset than the Flt3-Cre YFP+ subset.
Mouse gene entrez IDs were mapped to human ortholog based on Ensembl 87 annotation using Bioconductor package ''biomaRt.'' Genes were queried in the cbioportal TCGA pancreatic RNA-seq data through the R package ''cdgsr'' on 178 primary PDAC tumors. For association analysis with survival outcomes, we considered the gene signature using the averaged gene expression across all mapped genes (after centering each by their median). The gene signature was dichotomized by associated median to divide patients into the two groups of over-and under-expression. The Kaplan-Meier method was used to estimate empirical survival probabilities and log rank test to compare survival difference between patient groups. Hazard ratio from Cox proportional hazard model was reported with 95% confidence interval.
Human PDAC TAM Profiling
For gene expression profiling in PDAC patients, tissues were freshly obtained from 9 patients at pancreaticoduodenectomy, digested into single cell suspension using the protocol described above, stained with indicated antibodies, and processed for cell isolation using Aria-II (BD Biosciences). Cells were directly sorted into RNA lysis buffer (Omega Biotek). RNA was isolated using the EZNA kit (Omega Biotek) according to instructions by the manufacturer. cDNA was synthesized using the qScript Supermix (Quanta). cDNA targets were pre-amplified for 12 cycles, followed by QPCR analyses (Taqman, Thermo Fisher).
Quantitation and Statistical Analysis
Statistical analysis was performed using Unpaired Student's t test, Mann-Whitney U test, Wilcoxon matched-pairs signed rank test, or ANOVA analysis as appropriate for the dataset. Data in bar graphs are displayed as means ± SEM. Statistical significance is displayed as *p < 0.05.
DATA AND SOFTWARE AVAILABILITY
All software packages used are publically available thru commercial vendors.
